Abstract
Objective: To investigate the relationships among serum silencing information regulator 2-related enzyme 1 (SIRT1) expression levels, endothelial cell-specific molecule-1 (ESM-1), and fibroblast growth factor-21 (FGF21) and treatment results in patients with acute respiratory distress syndrome (ARDS) associated with sepsis.
Methods: A total of 140 patients with sepsis-related ARDS were selected and divided into a good outcome group of 96 patients and a poor outcome group of 44 patients according to the treatment outcome. The levels of serum SIRT1, ESM-1 and FGF21 were compared between the two groups; the correlations between serum SIRT1, ESM-1, and FGF21 and the severity of the disease as well as the treatment outcome were analyzed; and the predictive value of serum SIRT1, ESM-1 and FGF21 for treatment outcomes was evaluated.
Results: Compared to the group with a favorable outcome, the bad outcome group's serum SIRT1 level was lower, while the ESM-1 and FGF21 levels were significantly greater than those in the good outcome group (P<0.05). Serum SIRT1 levels steadily declined in patients with mild, moderate, and severe illness, while ESM-1 and FGF21 levels steadily rose (P<0.05). ESM-1 and FGF21 showed a positive association with illness severity (P<0.05), while serum SIRT1 showed a negative correlation (P<0.05) with disease severity, according to Spearman correlation analysis. Partial correlation analysis revealed that the serum SIRT1, ESM-1, and FGF21 levels were significantly correlated with the treatment outcomes of patients with sepsis-related ARDS (P<0.05). Serum SIRT1, ESM-1, and FGF21 levels and treatment outcomes were strongly correlated (P<0.05) in patients with sepsis-related ARDS. Serum SIRT1, ESM-1, and FGF21 areas under the curve (AUCs) for predicting the course of treatment for patients with ARDS associated with sepsis were 0.742, 0.838, and 0.796, respectively. The sensitivity was 77.27%, 77.27%, and 70.45%, and the specificity was 64.58%, 81.25%, and 87.50%, respectively. For patients with sepsis-related ARDS, the combined prediction of the three markers' AUC for treatment outcome was 0.939, with a sensitivity of 88.64% and a specificity of 83.33%, which was significantly greater than the individual predictive value of the three indicators alone (P< 0.05).
Conclusion: The levels of serum SIRT1, ESM-1 and FGF21 in patients with sepsis-related ARDS are strongly connected with both the efficacy of treatment and the severity of the illness, have the ability to independently predict treatment outcomes, and have a greater combined predictive value.
Keywords
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.